EXPANDED ACCESS POLICY – COMPANY DOES NOT PROVIDE EXPANDED ACCESS T3D Therapeutics, Inc. (T3D) is committed to bringing new, innovative therapies to patients by conducting rigorous clinical trials and obtaining marketing approval by the FDA and other regulatory authorities. T3D is developing promising new therapies to address the unmet medical needs of patients suffering from seriously debilitating diseases. We currently have a late stage investigational medicine in our product pipeline for the treatment of Alzheimer’s disease. Our goal is to provide access to our medicines at the appropriate time and in a manner that is most beneficial to the relevant patient population. We believe enrollment in our ongoing clinical trials is the safest and most effective way of achieving this goal. We do recognize that some patients will not be eligible for our clinical trials and may wish to access our products through expanded access. However, at this time, we do not have the resources available to offer expanded access use of our investigational medicines. We encourage all patients and physicians who are interested in accessing our investigational medicines to visit the clinical trial section of our website to find out about enrolling. https://clinicaltrials.gov/ct2/show/NCT04251182 T3D Therapeutics may revise this expanded access policy at any time. Additionally, the posting of this policy by T3D Therapeutics, Inc. does not serve as a guarantee of access to any specific investigational new drug by any individual patient. If you have any questions, please reach out to us at firstname.lastname@example.org . You can find further contact details on the Contact Us page of our website.